Moberg Pharma AB (publ) (STO:MOB)
Sweden · Delayed Price · Currency is SEK | Market Cap | 512.31M +41.8% |
| Revenue (ttm) | 13.54M +38.0% |
| Net Income | -27.24M |
| EPS | -0.58 |
| Shares Out | 47.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,564 |
| Average Volume | 137,388 |
| Open | 10.78 |
| Previous Close | 10.90 |
| Day's Range | 10.40 - 10.94 |
| 52-Week Range | 7.25 - 14.12 |
| Beta | 1.06 |
| RSI | 48.83 |
| Earnings Date | May 12, 2026 |
About Moberg Pharma AB
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden. [Read more]
Full Company ProfileFinancial Performance
In 2025, Moberg Pharma AB's revenue was 13.54 million, an increase of 37.99% compared to the previous year's 9.81 million. Losses were -27.24 million, -89.32% less than in 2024.
Financial StatementsNews
Moberg Pharma AB Transcript: Stora Aktiedagarna 2026
A topical terbinafine treatment for nail fungus achieved rapid market leadership in Sweden and Norway, with strong clinical results and a premium price. Expansion is underway across Europe via partnerships, with regulatory approval for Lamisil branding as a near-term milestone.
Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
STOCKHOLM , Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Eur...
Moberg Pharma AB Earnings Call Transcript: Q4 2024
Terclara solidified market leadership in Sweden and began expansion into Norway, with further EU rollouts planned for 2026. U.S. launch is delayed pending new clinical data, but the company remains well-financed and focused on European growth.
Moberg Pharma AB Transcript: Study Update
The North American phase III study for MOB-015 did not meet its primary endpoint, with only 1.5% achieving complete cure and lower mycological cure rates than prior studies. Strategic focus will shift to Europe, leveraging strong results and market leadership in Sweden, while U.S. regulatory plans are put on hold.
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
STOCKHOLM , Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing ...
Moberg Pharma AB Earnings Call Transcript: Q3 2024
Terclara led the Swedish market in Q3, achieving 34% value and 78% unit share, and drove 41% category growth. U.S. phase III results may fall short of expectations, but European expansion remains on track with approvals in 13 countries.
Moberg Pharma AB Transcript: Study Update
Blinded interim data from a North American phase III study showed lower-than-expected clinical cure rates for MOB-015, raising the risk of not meeting the primary endpoint and impacting U.S. commercialization prospects. EU and Canadian launches remain on track, with the EU launch dependent on supply chain approvals.
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
STOCKHOLM , Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Pha...
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
STOCKHOLM , June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinar...